Hybrigenics General Meetings
Only the french version of documents is available
Shareholders
Institutional Shareholders Since its creation 1997, the company gathered € 58 millions, in three steps.
The first step was made with Venture Capital funds, Apax being one of them since the beginning. In three rounds, € 49 millions were raised, which were invested in the growth of the company.
The second step occurred in December 2007, when the company went public after an IPO on Alternext, with 6.2 millions raised.
The last step was a private placement with qualified investors, for € 2.8 millions in December 2009.
Apax Partners is one of the world's leading private equity investment firms. Apax is dedicated to helping entrepreneurs build world class companies. The company track record of working with entrepreneurs from start up to leveraged transactions of over Euro 1 billion is exceptional. Since 1995 alone 46 of their companies went public on stock markets around the world. At point of entry to market these companies had a collective market capitalisation of over Euro 23 billion. Apax Partners currently has Euro 12 billion under management or advice around the world, and 330 companies in the portfolio. Apax 160 investment professionals operate from twelve offices in nine countries.
Life Sciences Partners is a European venture capital firm based in Amsterdam (Netherlands) and Munich (Germany), focusing on human biotechnology and medical devices. The fund has € 170 million capital under management and has invested in a broad range of companies in Europe, the US and Israel. The partners of the fund have a proven track record in venture capital and the life sciences, among others through Board Seats at listed companies as Qiagen, Quadrant, Rhein Biotech, Biora and Crucell.
|
